Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Alvocidib Biomarker-driven Phase 2 AML Study
NCT02520011 · Sumitomo Pharma America, Inc. · PHASE2 · terminated · last registry update 2023-11-15 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to slow enrollment, the extensive time projected to conclude the study hypothesis rendered the study no longer reasonably feasible to complete.” | Open Targets' class: insufficient enrollment | Registry record, Sumitomo Pharma America, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CDK2 in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision